# Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

> **NCT00193544** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 40 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Arsenic Trioxide
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00193544
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2005-10
- **Final completion:** 2009-01
- **Target enrollment:** 40 (—)
- **Last updated:** 2009-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193544, "Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00193544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*